U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 10 of 35 results

Status:
US Approved Rx (2021)
First approved in 2015

Class (Stereo):
CHEMICAL (ACHIRAL)



Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. PAH is a relatively rare disease with usually a poor prog...
Status:
US Approved Rx (2013)
First approved in 2013

Class (Stereo):
CHEMICAL (ACHIRAL)



Macitentan is an orally active, dual endothelin receptor antagonist with tissue targeting properties. Macitentan inhibits both ETA and ETB receptors and prevents them from binding to ET-1. Macitentan displays high affinity and sustained occupancy of ...
Status:
US Approved Rx (2022)
First approved in 2013

Class (Stereo):
CHEMICAL (ACHIRAL)



Riociguat is a potent, oral stimulator of soluble guanylate cyclase (sGC). It is the first member of a novel class of compounds, being developed by Bayer as an investigational, oral treatment to target a key molecular mechanism underlying pulmonary h...
Status:
US Approved Rx (2022)
First approved in 2007

Class (Stereo):
CHEMICAL (RACEMIC)



Ambrisentan (alternative Names: BSF 208075; GSK 1325760; GSK1325760A; Letairis) is an endothelin receptor antagonist that is selective for the endothelin type-A (ETA) receptor. The chemical name of ambrisentan is (+)-(2S)-2-[(4,6-dimethylpyrimidin-2-...
Status:
US Approved Rx (2024)
First approved in 2004

Class (Stereo):
CHEMICAL (EPIMERIC)



Iloprost is a second generation structural analog of prostacyclin (PGI) with about ten-fold greater potency than the first generation stable analogs, such as carbaprostacyclin. Iloprost binds with equal affinity to human prostacyclin (Prostanoid IP) ...
Status:
US Approved Rx (2009)
First approved in 2002

Class (Stereo):
CHEMICAL (ABSOLUTE)



Treprostinil (marketed under the trade names Remodulin for infusion) is a vasodilator that is used for the treatment of pulmonary arterial hypertension. Pulmonary arterial hypertension (PAH) is a disease in which blood pressure is abnormally high in ...
Status:
US Approved Rx (2019)
First approved in 2001

Class (Stereo):
CHEMICAL (ACHIRAL)



Bosentan is a dual endothelin receptor antagonist important in the treatment of pulmonary artery hypertension (PAH). It is licensed in the United States, the European Union and other countries by Actelion Pharmaceuticals for the management of PAH und...
Status:
US Approved Rx (2013)
First approved in 1998

Class (Stereo):
CHEMICAL (ACHIRAL)



Sildenafil (Viagra, Revatio) is a PDE5 inhibitor which was approved by FDA for the treatment of erectile disfunction and adults with pulmonary arterial hypertension. Upon administration sildenafil inhibits PDE5 and results in elevated level of cyclic...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



Lificiguat (YC-1) [3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole], a chemically synthetic benzylindazole compound, is a direct soluble guanylate cyclase activator. It possessed antiplatelet activity. YC-1 inhibits Hypoxia-inducible factor-1 (HIF-1)....
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



Furegrelate (previously known as U-63557A), a selective orally active thromboxane synthase inhibitor, with potential for the treatment of various diseases including hypertension, thrombosis, and renal disorders, arrhythmias, but these studies were di...